Drug Search Results
More Filters [+]

Basimglurant

Alternative Names: basimglurant, ro4917523, noe-101, noe101, noe 101
Latest Update: 2024-09-07
Latest Update Note: Clinical Trial Update

Product Description

Basimglurant is a highly promising antidepressant drug now in clinical development for depression. a novel negative allosteric modulator of metabotropic glutamate receptor 5 (Sourced from: https://pubmed.ncbi.nlm.nih.gov/26219727/)

Mechanisms of Action: MGLUR5 Modulator

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: Fast Track - Neuralgia|Trigeminal Neuralgia *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Basimglurant

Countries in Clinic: Denmark, Germany, India, Israel, Italy, Poland, Spain, Turkey, United Kingdom, United States

Active Clinical Trial Count: 5

Highest Development Phases

Phase 3: Trigeminal Neuralgia

Phase 2: Tuberous Sclerosis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Basimglurant in children, adolescents, and young adults with Tuberous Sclerosis Complex

P2

Active, not recruiting

Tuberous Sclerosis

2026-09-21

NOE-TSC-201

P2

Not yet recruiting

Tuberous Sclerosis

2025-08-08

A Phase II/III efficacy and safety study of basimglurant in patients with trigeminal neuralgia

P3

Active, not recruiting

Trigeminal Neuralgia

2025-05-05

NOE-TGN-201

P3

Recruiting

Trigeminal Neuralgia

2025-01-31

Recent News Events